American Diabetes Association recommended sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) for T2DM with chronic kidney disease (CKD) or high risk of chronic kidney disease treatment [2, 6]. Here, SLC5A2 is linked to chronic kidney disease.